Florbenazine F-18
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Florbenazine F-18
- Accession Number
- DB14945
- Description
Florbenazine F-18 is under investigation in clinical trial NCT01515384 (A Trial of 18F-AV-133 Positron Emission Tomography (PET)).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 364.492
Monoisotopic: 364.239156561 - Chemical Formula
- C21H32FNO3
- Synonyms
- 18F-AV-133
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- KM31LBX59H
- CAS number
- 956903-29-0
- InChI Key
- GNKGXQHHUUEYQV-WTHAECTESA-N
- InChI
- InChI=1S/C21H32FNO3/c1-14(2)9-16-13-23-7-5-15-10-21(26-8-4-6-22)20(25-3)11-17(15)18(23)12-19(16)24/h10-11,14,16,18-19,24H,4-9,12-13H2,1-3H3/t16-,18-,19-/m1/s1/i22-1
- IUPAC Name
- (2R,3R,11bR)-9-[3-(¹⁸F)fluoropropoxy]-10-methoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol
- SMILES
- COC1=C(OCCC[18F])C=C2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3C2=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 26338549
- ChEMBL
- CHEMBL1780010
- ZINC
- ZINC000100529342
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2, 3 Completed Diagnostic Lewy Body Parkinson's Disease / Parkinson's Disease (PD) / Primary Parkinsonism 1 1 Completed Diagnostic Type 2 Diabetes Mellitus 1 1 Terminated Diagnostic Type 1 Diabetes Mellitus / Type 2 Diabetes Mellitus 1 1, 2 Completed Diagnostic Alzheimer's Disease (AD) / Diffuse Lewy Body Disease / Parkinson's Disease (PD) 1 Not Available Completed Not Available Type 1 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0472 mg/mL ALOGPS logP 3.2 ALOGPS logP 2.93 ChemAxon logS -3.9 ALOGPS pKa (Strongest Acidic) 14.85 ChemAxon pKa (Strongest Basic) 8.18 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 41.93 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 101.86 m3·mol-1 ChemAxon Polarizability 42.07 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on May 20, 2019 08:37 / Updated on June 12, 2020 10:53
